Evidence map›Paper›PMID 31156718›Full record

ArticleTherapeutic advances in neurological disorders2019

Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson's disease: A pilot study.

Marilena Gubbiotti, Antonella Conte, Savino M Di Stasi, Nicola Tambasco, Antonella Giannantoni

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in neurological disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Clinical Utility of βResearch and reports in urology · 2022
    Review
  7. Current Management and Emerging Therapies in Multiple System Atrophy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Marilena GubbiottiSerafico Institute of Assisi, Research Centre 'InVita', Assisi (Perugia), Italy.
Antonella ConteIRCCS Neuromed Institute, Pozzilli, Province of Isernia, Italy Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy.
Savino M Di StasiDepartment of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Nicola TambascoNeurology Clinic, University of Perugia, Perugia, Italy.
Antonella GiannantoniDepartment of Medical and Surgical Sciences and Neurosciences, University of Siena, Siena, Italy.
Assisi Foundation of Memphis · USIstituto Neurologico Mediterraneo · ITUniversity of Perugia · ITUniversity of Rome Tor Vergata · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe investigated the effectiveness and safety of mirabegron oral treatment in a group of patients with Parkinson's disease (PD) and overactive bladder (OAB), refractory to antimuscarinics. MATERIALS AND

methodsThirty patients with PD and refractory OAB were prospectively included in the study. At baseline, motor symptoms, severity of disease and cognitive status were assessed with the Hoehn-Yahr Scale, the Unified Parkinson's disease Rating Scale, the Mini Mental State examination and the Montreal Cognitive Assessment. At baseline, urinary symptoms, satisfaction with treatment and the impact of urinary incontinence on quality of life (QoL) were assessed with the 3-day voiding diary, the Visual Analogue Scale (VAS), the Incontinence-QoL questionnaire and urodynamics. Patients started assuming mirabegron 50 mg tablets once daily. Evaluation of urinary symptoms and related questionnaires, motor symptoms, severity of PD and uroflowmetry with postvoid residual volume measurement were then repeated at the 3- and 6-month follow up. Side effects were also noted.

resultsAt baseline, the most frequently reported urinary symptoms were: urinary urgency (present in all the patients), urge urinary incontinence in 28/30 (93.3%) and increased daytime urinary frequency in 25 (83.3%) patients. At the 3-month follow up, 7 out of the 30 patients achieved a complete urinary continence. Significant improvements in VAS and Incontinence-QoL scores were observed in 24 patients. These benefits were maintained for the whole observation period. Four patients discontinued treatment due to poor efficacy, and two due to the cost of the drug.

conclusionsMirabegron is a safe and effective treatment in patients with PD and OAB refractory to anticholinergics in the short-term follow up.

Indexed as

mirabegronoveractive bladderParkinson’s disease

Identifiers

PMID31156718
PMCPMC6515844
OpenAlexW2944153925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.